Log In
Print
BCIQ
Print
Print this Print this
 

parsatuzumab (RG7414, RO5490248)

  Manage Alerts
Collapse Summary General Information
Company Roche
DescriptionHumanized mAb against EGF-like-domain multiple 7 (EGFL7)
Molecular Target EGF-like-domain multiple 7 (EGFL7)
Mechanism of ActionAngiogenesis inhibitor; Antibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat solid tumors
Regulatory Designation

Partner

Chugai Pharmaceutical Co. Ltd.; Genentech Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today